Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cemiplimab

- PMLiVE

Sanofi joins WHO-backed diabetes mHealth programme

Becomessole pharma partner for Be Healthy, Be Mobile's diabetes arm

Sanofi reception

Sanofi gets green light for Lantus follow-up Toujeo

Once-daily basal insulin gains FDA approval for diabetes

France flag

French pharma growth restricted by generics

New analysis finds country’s market value will grow only modestly in the coming years

- PMLiVE

Smith & Nephew invests in new tech that can ‘see’ through skin

Hopes to use tech for detecting skin cancer and help with wound care

- PMLiVE

Sanofi’s CEO search ends as Bayer’s Brandicourt takes the job

He will begin leading the French pharma company on April 2

- PMLiVE

Apotex latest to file Neupogen biosimilar in the US

White blood cell stimulator could be on the market this year

- PMLiVE

Rumour mill intensifies around Bayer’s Brandicourt for Sanofi

Could be named Sanofi chief executive as soon as next March

- PMLiVE

Takeda’s lung cancer drug motesanib flunks another trial

Drug was unable to extend progression-free survival in study of 400 patients

- PMLiVE

Decision to withdraw Jevtana in England ‘flawed’

Urologists and oncologists attack NHS England’s de-listing of Sanofi’s drug

- PMLiVE

FDA outlines its plans to simplify DTC ads for consumers

Hopes customer-friendly terminology will aid healthcare decisions

Sanofi reception

Generic competition for Sanofi’s Renvela hits UK market

Teva and others launch cheaper versions of the chronic kidney disease drug

Sanofi reception

Generic competition for Sanofi’s Renvela hits UK market

Teva and others launch cheaper versions of the chronic kidney disease drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links